Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • ewirtz555 ewirtz555 Dec 15, 2012 9:48 AM Flag

    What´s next?

    "The Phase 1 study of ISIS-CRPRx was a blinded, randomized, placebo-controlled, dose-escalation study designed to #$%$ the safety and pharmacokinetic profile of ISIS-CRPRx as well as to #$%$ the initial effects of the drug on baseline CRP levels. ISIS-CRPRx was evaluated in single and multiple doses ranging from 50 mg per week to 600 mg per week in 80 healthy volunteers. In all but one cohort, Isis enrolled subjects who had normal (generally undetectable to less than 2 mg/L) CRP levels. In the 600 mg per week multi-dose cohort, Isis enrolled eight subjects with elevated levels of CRP. The subjects enrolled in this cohort had an average CRP level at baseline of approximately 3.0 mg/L. After only three weeks of dosing, the six subjects who received ISIS-CRPRx had an average CRP level of 0.76 mg/L, which is within the normal range of CRP and represents an average reduction of greater than 70 percent compared to placebo. Subjects receiving placebo remained elevated above 3.0 mg/L. In all subjects receiving the drug, it was well tolerated with no serious adverse events. "

    Hi, thanks!

    " After only three weeks of dosing, the six subjects who received ISIS-CRPRx had an average CRP level of 0.76 mg/L, which is within the normal range of CRP and represents an average reduction of greater than 70 percent compared to placebo"

    I expect they´ll confirm the reduction of CRP levels. The wild card is which impact the reduction of CRP levels will have or not

 
ISIS
51.75+3.00(+6.15%)4:00 PMEDT